Total Value in 2013: $5,960.77M* Number of Deals in 2013: 93 Company (Location) Company (Location) Value (M) Type/Product Area Terms/Details Date FEBRUARY Ablynx NV (Ghent, Belgium) Spirogen Ltd. (London) ND Research collaboration to evaluate the potential of a cancer drug conjugate combining Spirogen's cytotoxic drugs, pyrrolobenzodiazepines and associated linker technology, with Nanobodies generated Ablynx will provide access to Nanobodies against an undisclosed target, and Spirogen will

In the current fiscal environment, everything in the U.S. budget is open to scrutiny. Fortunately for the biodefense industry, protecting the nation from bioterrorism tends to have bipartisan support, especially when potential threats get extensive news coverage. This month alone, there have been ricin-laced letters sent to President Barack Obama, Sen. Roger Wicker and Mississippi judge Sadie Holland, and claims that the chemical weapon sarin was used during the Syrian civil war. Funding for

Company (Location) Company (Location) Value (M) Type/Product Area Terms/Details Date Modified Agreements FEBRUARY Selexis SA (Geneva) Amgen Inc. (Thousand Oaks, Calif.) ND Expanded R&D license deal to include an evaluation of Selexis' SURE CHO-M Cell Line for R&D Amgen will be able to evaluate the SURE CHO-M Cell Line in conjunction with the Selexis SUREtech Vectors for improved R&D 2/21/13 Spectrum Pharmaceuticals Inc. (Henderson, Nev.) Allergan Inc. (Irvine, Calif.) $345.5 Deal under which

A quick scan through the drug pipelines of many biotechnology and pharmaceutical companies will reveal a significant number of drugs under development that have received "orphan drug status." Yet, it wasn't all that long ago that orphan drugs were considered too small to devote valuable R&D resources. As a consequence they did not feature prominently on the product development radar screens of either pharma or biotech companies. However, that situation has changed in a hurry. Small patient

Company (Location) Company (Location) Value (M) Type/Product Area Terms/Details Date DECEMBER Cevec Pharmaceuticals GmbH (Cologne, Germany) Yuhan Corp. (Seoul, South Korea) ND CAP-Technology licensing deal enabling Yuhan to use Cevec's CAP-T and CAP cell expression systems for the production and development of various therapeutic proteins Financial terms were not disclosed 12/21/12 GlaxoSmithKline plc (London) The University of Texas MD Anderson Cancer Center (Houston) $335 Research

Company (Location) Company (Location) Value (M) Type/Product Area Terms/Details Date I. Modified Agreements DECEMBER Soligenix Inc. (Princeton, N.J.) Sigma-Tau Pharmaceuticals Inc. (Gaithersburg, Md.) ND Soligenix has regained the North American and European commercial rights to oral BDP through an amendment of its collaboration agreement The company is now free to commercialize or enter into commercialization agreements with other parties 12/28/12 JANUARY Adimab LLC (Lebanon, N.H.) Merck & Co

Company (Location) Company (Location) Value (M) Type/Product Area Terms/Details Date DECEMBER Alimera Sciences Inc. (Atlanta) Quintiles Commercial Europe Ltd. (Berkshire, UK) ND A master services agreement for the commercial launch of Iluvien in certain European countries, beginning with Germany and followed by the UK and France The product is designed to treat chronic diabetic macular edema considered insufficiently responsive to available therapies 12/6/12 Apexigen Inc. (Burlingame, Calif

Total Value in 2013: $4,303M* Number of Deals in 2013: 68 Company (Location) Company (Location) Value (M) Type/Product Area Terms/Details Date DECEMBER AIMM Therapeutics NV (Amsterdam, the Netherlands) Cosmo Pharmaceuticals SpA (Milan, Italy) ND Strategic partnership to develop oral diagnostic and therapeutic antibodies for gastrointestinal diseases including colon carcinoma Cosmo will formulate human monoclonal antibodies generated by AIMM in an extended-release form exploiting its MMX

Company Company Deal Value Inspiration Biopharmaceuticals Inc. Baxter International Inc. $700M Chiasma Inc. Roche AG $595M Edison Pharmaceuticals Inc. Dainippon Sumitomo Pharma Co. $545M Moderna Therapeutics Inc. AstraZeneca plc $420M Isis Pharmaceuticals Inc. Roche AG $392M Ambrx Inc. Astellas Pharma Inc. $300M Resolve Therapeutics LLC Takeda Pharmaceutical Co. Ltd. $255M Opexa Therapeutics Inc. Merck Serono SA $225M BIND Therapeutics Inc. Pfizer Inc. $210M Ra Pharmaceuticals Inc. Merck & Co

Congress is running out of patience with the SEC's continued delay in implementing part of the Jumpstart Our Business Startups Act that was supposed to be in place last year. The FDA said it won't approve generics based on Purdue Pharma LP's original OxyContin, which has been replaced with a formulation less prone to abuse. Amgen Inc. agreed to pay $24.9 million to settle federal allegations that it gave kickbacks to long-term care pharmacy providers to switch Medicare and Medicaid beneficiaries

"We believe this is getting the attention it deserves. We believe the FDA is engaged in this in the way we would like to see them engaged. They're asking very good questions." – Chris Garabedian, president and CEO of Sarepta Therapeutics Inc., discussing the FDA's request for additional information from its eteplirsen dataset before determining the new drug application filing pathway "We have a fairly unique platform. I know everybody says the same thing, but we have found a way that allows for

Financings Agenus Inc. retired its outstanding $39 million 8 percent senior secured convertible notes issued in 2006. Allecra Therapeutics GmbH raised $19.6 million in a Series A round. Auris Medical AG landed $50.8 million in its Series C funding round. ChemoCentryx Inc. commenced its underwritten public offering of $60 million in common stock. Durata Therapeutics Inc. priced a $50 million public offering, selling 7.15 million shares at $7 each. Kamada Ltd. filed for an IPO to gain a U.S